{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:46:25Z","timestamp":1791870385954,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Study Objectives<\/jats:title>\n                    <jats:p>These post-hoc analyses of SURMOUNT-OSA evaluated patient-reported outcome measures (PROMs) and objective assessments, considering participants\u2019 baseline characterization of fatigue, sleepiness, snoring, and sleep quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>SURMOUNT-OSA included two 52-week randomized, placebo-controlled studies of tirzepatide (10\/15\u00a0mg) in participants with moderate-to-severe obstructive sleep apnea (OSA) and obesity (Study 1: participants not using positive airway pressure [PAP]; Study 2: participants using PAP). Participants were grouped by self-reported baseline severity of fatigue (Non-fatigued\/Fatigued), sleepiness (Non-sleepy\/Sleepy), snoring (Non-snoring\/Snoring), and sleep quality (Good\/Poor). Changes in PROMs and objective assessments from baseline to Week 52 were assessed per subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In both studies, tirzepatide treatment was consistently associated with greater improvements in PROMs and objective assessments than placebo. In Study 1, tirzepatide-treated participants in the Fatigued subgroup had numerically greater improvements versus Non-fatigued subgroup in Functional Outcomes of Sleep Questionnaire Activity Level (least-square means [LSM] difference from placebo: 0.33 vs. 0.05), SF-36v2 Vitality, (8.5 vs. 1.0), and SF-36v2 General Health scores (6.2 vs. 1.4). The Sleepy subgroup showed numerically greater improvements versus Non-sleepy subgroup in Patient-Reported Outcomes Measurement Information System (PROMIS) Short-Form Sleep-Related Impairment 8a scores (LSM difference: \u20137.1 vs. \u20131.6) while the Poor sleep quality subgroup had numerically greater improvements versus Good sleep quality subgroup in PROMIS Short-Form Sleep Disturbance scores (LSM difference: \u20135.8 vs. \u20131.2). Changes in PROMs were similar in both snoring subgroups. Study 2 patterns were generally consistent with Study 1. Tirzepatide treatment was associated with similar improvements in objective assessments (apnea-hypopnea index, sleep apnea-specific hypoxic burden, weight, OSA remission) across all symptom severity subgroups in both studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Across subgroups, tirzepatide treatment was associated with greater improvements in PROMs than placebo. Participants with worse fatigue, sleepiness, and sleep quality at baseline generally had larger improvements on related PROMs than those with milder symptoms. Tirzepatide treatment was also associated with greater improvements in objective assessments versus placebo, though these changes were generally similar across baseline symptom severity subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>Registered at ClinicalTrials.gov under \u201cObstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (SURMOUNT-OSA)\u201d; https:\/\/clinicaltrials.gov\/study\/NCT05412004; registration number: NCT05412004<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/sleep\/zsag184","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:39:04Z","timestamp":1783424344000},"source":"Crossref","is-referenced-by-count":0,"title":["Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analyses"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-8652","authenticated-orcid":false,"given":"Chisom","family":"Kanu","sequence":"first","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shraddha","family":"Shinde","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Falcon","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Bednarik","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy Chang","family":"Xie","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Trice","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Weaver","sequence":"additional","affiliation":[{"name":"School of Nursing, University of Pennsylvania , Philadelphia, PA ,","place":["United States"]},{"name":"College of Nursing, University of Illinois Chicago , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"8","key":"2026101301124083700_ref1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S2213-2600(19)30198-5","article-title":"Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis","volume":"7","author":"Benjafield","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2026101301124083700_ref2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s13679-020-00369-y","article-title":"Sleep apnea, obesity, and disturbed glucose homeostasis: epidemiologic evidence, biologic insights, and therapeutic strategies","volume":"9","author":"Pugliese","year":"2020","journal-title":"Curr Obes Rep"},{"issue":"9918","key":"2026101301124083700_ref3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0140-6736(13)60734-5","article-title":"Adult obstructive sleep apnoea","volume":"383","author":"Jordan","year":"2014","journal-title":"Lancet."},{"issue":"15","key":"2026101301124083700_ref4","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1056\/NEJMcp1816152","article-title":"Obstructive sleep apnea in adults","volume":"380","author":"Veasey","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2026101301124083700_ref5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1513\/AnnalsATS.202006-696FR","article-title":"Excessive daytime sleepiness in obstructive sleep Apnea. Mechanisms and clinical management","volume":"18","author":"Lal","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"2026101301124083700_ref6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11325-008-0192-8","article-title":"Predictors of fatigue in obstructive sleep apnea","volume":"12","author":"Mills","year":"2008","journal-title":"Sleep Breath"},{"issue":"8","key":"2026101301124083700_ref7","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59081459","article-title":"An update on obstructive sleep apnea syndrome\u2014a literature review","volume":"59","author":"Platon","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"2026101301124083700_ref8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s11325-009-0252-8","article-title":"Arousal frequency is associated with increased fatigue in obstructive sleep apnea","volume":"13","author":"Yue","year":"2009","journal-title":"Sleep Breath"},{"key":"2026101301124083700_ref9","doi-asserted-by":"publisher","first-page":"630162","DOI":"10.3389\/fpsyt.2021.630162","article-title":"The complex interaction between the major sleep symptoms, the severity of obstructive sleep apnea, and sleep quality","volume":"12","author":"Frangopoulos","year":"2021","journal-title":"Front Psych"},{"key":"2026101301124083700_ref10","volume-title":"Novel drug approvals for 2022","author":"U.S. Food and Drug Administration (FDA)","year":"2022"},{"key":"2026101301124083700_ref11","volume-title":"FDA approves new medication for chronic weight management","author":"U.S. Food and Drug Administration (FDA)","year":"2023"},{"key":"2026101301124083700_ref12","volume-title":"FDA approves first medication for obstructive sleep apnea","author":"U.S. Food and Drug Administration","year":"2024"},{"issue":"13","key":"2026101301124083700_ref13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"2026101301124083700_ref14","doi-asserted-by":"publisher","first-page":"106719","DOI":"10.1016\/j.sleep.2025.106719","article-title":"Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity","volume":"134","author":"Kanu","year":"2025","journal-title":"Sleep Med"},{"issue":"2","key":"2026101301124083700_ref15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.chest.2019.09.002","article-title":"Phenotypic subtypes of OSA: a challenge and opportunity for precision medicine","volume":"157","author":"Zinchuk","year":"2020","journal-title":"Chest."},{"issue":"6","key":"2026101301124083700_ref16","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1183\/09031936.00032314","article-title":"The different clinical faces of obstructive sleep apnoea: a cluster analysis","volume":"44","author":"Ye","year":"2014","journal-title":"Eur Respir J"},{"issue":"4","key":"2026101301124083700_ref17","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/009286150804200402","article-title":"Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials","volume":"42","author":"Mallinckrodt","year":"2008","journal-title":"Drug Inf J"},{"key":"2026101301124083700_ref18","doi-asserted-by":"crossref","DOI":"10.1002\/9781119013563","volume-title":"Statistical Analysis with Missing Data","author":"Little","year":"2002"},{"issue":"2","key":"2026101301124083700_ref19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1164\/rccm.201912-2511OC","article-title":"Effects of weight loss on obstructive sleep apnea severity. Ten-year results of the Sleep AHEAD study","volume":"203","author":"Kuna","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2026101301124083700_ref20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/dom.16046","article-title":"Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: results from the SURMOUNT-1 study","volume":"27","author":"Gudzune","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2026101301124083700_ref21","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s13300-025-01723-w","article-title":"Tirzepatide was associated with improved health-related quality of life in adults with obesity or overweight and type 2 diabetes: results from the phase 3 SURMOUNT-2 trial","volume":"16","author":"Hunter Gibble","year":"2025","journal-title":"Diabetes Ther"},{"issue":"Supplement_1","key":"2026101301124083700_ref22","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.042","article-title":"5183 Tirzepatide improved health-related quality of life in people with obesity or overweight: results from SURMOUNT-4 phase 3 trial. J Endocr","volume":"8","author":"Gibble","year":"2024","journal-title":"Soc."},{"key":"2026101301124083700_ref23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.sleep.2016.06.001","article-title":"Comparative efficacy of CPAP, MADs, exercise-training, and dietary weight loss for sleep apnea: a network meta-analysis","volume":"30","author":"Iftikhar","year":"2017","journal-title":"Sleep Med"},{"issue":"12","key":"2026101301124083700_ref24","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.soard.2023.07.007","article-title":"The efficacy of bariatric surgery on pulmonary function and sleep architecture of patients with obstructive sleep apnea and co-morbid obesity: a systematic review and meta-analysis","volume":"19","author":"Qin","year":"2023","journal-title":"Surg Obes Relat Dis"},{"issue":"23","key":"2026101301124083700_ref25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11236890","article-title":"Impact of a weight-loss rehabilitation program on sleep apnea risk and subjective sleepiness in patients with overweight\/obesity: the DietSleep study","volume":"11","author":"Bailly","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"2026101301124083700_ref26","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.chest.2019.11.011","article-title":"Responsiveness of patient-reported outcomes to treatment among patients with type 2 diabetes mellitus and OSA","volume":"157","author":"Donovan","year":"2020","journal-title":"Chest."},{"issue":"2","key":"2026101301124083700_ref27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.5664\/jcsm.7638","article-title":"Treatment of adult obstructive sleep apnea with positive airway pressure: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment","volume":"15","author":"Patil","year":"2019","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"2026101301124083700_ref28","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/jsr.12558","article-title":"Night-to-night variability of obstructive sleep apnea","volume":"26","author":"St\u00f6berl","year":"2017","journal-title":"J Sleep Res"},{"issue":"4","key":"2026101301124083700_ref29","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsae295","article-title":"Night-to-night variability in obstructive sleep apnea severity, the physiological endotypes, and the frequency of flow limitation","volume":"48","author":"Hynes","year":"2024","journal-title":"Sleep."},{"issue":"3","key":"2026101301124083700_ref30","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s11325-020-02270-3","article-title":"Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea","volume":"25","author":"Weaver","year":"2021","journal-title":"Sleep Breath"}],"container-title":["SLEEP"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsag184\/68709948\/zsag184.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/49\/10\/zsag184\/68709948\/zsag184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/49\/10\/zsag184\/68709948\/zsag184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:12:49Z","timestamp":1791868369000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsag184\/8726390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,7,7]]},"published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsag184","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,7]]},"article-number":"zsag184"}}